Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024
Dana-Farber Cancer Institute presents novel breast cancer treatments and quality of life research at ESMO Congress 2024, including studies on targeted therapies and antibody-drug conjugates. Key presentations include Ann Partridge on unintended consequences of cancer care, Nancy Lin on DESTINYBreast-12, and Toni Choueiri on renal cell carcinoma. Other studies cover vitamin D supplementation, HIF-2α inhibitors, and supportive care interventions.
Highlighted Terms
Related News
Dana-Farber Cancer Institute presents novel breast cancer treatments and quality of life research at ESMO Congress 2024, including studies on targeted therapies and antibody-drug conjugates. Key presentations include Ann Partridge on unintended consequences of cancer care, Nancy Lin on DESTINYBreast-12, and Toni Choueiri on renal cell carcinoma. Other studies cover vitamin D supplementation, HIF-2α inhibitors, and supportive care interventions.